Document:

Exhibit 10.53
​
Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions.
​

Collaborative Research Agreement Amendment No. 10
This Amendment No. 10 is made and entered into as of the last date of signature (the “Amendment 10  Effective Date") to that certain Collaborative Research Agreement dated September 30, 2015 (as amended, the “Agreement”) by and between National Taiwan University at No. 1, Sec. 4, Roosevelt Road, Taipei, 10617 Taiwan (R.O.C) (hereinafter “NTU”) and PTC Therapeutics GT, Inc. (formerly Agilis Biotherapeutics), a Delaware corporation duly organized under law and having an address at 6 Kimball Lane, Suite 320, Lynnfield, Massachusetts, 01940 USA (hereinafter “COMPANY”). Capitalized terms herein shall have the meaning ascribed to them in the Agreement. To the extent of any conflict with the prior amendments to the Agreement, this Amendment 10 supersedes the prior amendments.
​
WHEREAS, the COMPANY and NTU previously amended the agreement via Amendments 1 through 9. In the previous amendments, the COMPANY and NTU agreed to a continue the active studies, including active Phase IIb Protocol studies and related research and appointing a new principal investigator; and an additional research project and corresponding increases in the budget for [**].   
​
NOW, THEREFORE, the COMPANY and NTU wish to further amend the Agreement as follows:
​
		1.	Modifications

​
a.Research Budget (Amendment No. 10).  For the calendar year beginning January 1, 2022 through the end of 2022, the estimated budget shall be [**] U.S. Dollars (USD$ [**]) per quarter, which amount is inclusive of NTU’s fees, based upon the fee schedule for the Services outlined in Attachment A. The actual amounts invoiced may vary depending upon [**].  Invoices shall reflect the fees due in U.S. Dollars and shall be sent to [**], with a copy to COMPANY’s project manager. Each invoice will include the Purchase Order numbers specific for each service fee as provided in Attachment A. 
​
COMPANY shall pay NTU within [**] of its receipt of each invoice. 
​
		2.	Effect of Amendment.  As of the Amendment Effective Date, this Amendment shall amend, modify and supersede, to the extent of any inconsistencies, the provisions of the Agreement.  Except as expressly modified by this Amendment, the Agreement shall remain in full force and effect.  Capitalized terms used in this Amendment and not otherwise defined shall have the meaning ascribed to such terms in the Agreement.  As of the Amendment Effective Date, any reference to the Agreement shall be deemed a reference to the Agreement as amended by this Amendment.

​
3.  General Provisions. 
a. Counterparts.  This Amendment may be executed in any one or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument.
​
b. Miscellaneous.  The Agreement, as amended by this Amendment, sets forth the entire understanding between and among the parties and there are no other understandings or promises, written or verbal, not set forth herein, relating specifically to the subject matter hereof.  The Agreement, as amended by this Amendment, supersedes any prior or contemporaneous agreements with respect to the subject matter hereof.
​
c. Headings. The headings and subheadings of the sections of this Amendment have been included solely for the ease of reference and do not form part of this Amendment.
​
IN WITNESS WHEREOF, both NTU and COMPANY have executed this Amendment10, in duplicate 

originals, electronic mail of PDFs or electronic signatures, by their respective and duly authorized officers on the day and year written.
​
​
	2

	​

	PTC THERAPEUTICS GT, INC.
	NATIONAL TAIWAN UNIVERSITY

	​
	​

	By: /s/ Matthew Klein
	By: /s/ Chung-Ming Kuan

	Authorized Signature
	Authorized Signature

	​
	​

	Matthew Klein, MD, MS, FACS
Chief Development Officer
	Printed Name & Title

	​
	​

	Date: 01-Nov-2021
	Date:

​

​EX-4.1

			
		  	Exhibit 4.1
		
	NUMBER	  	UNITS
	U-	  	
		
	SEE REVERSE FOR CERTAIN DEFINITIONS	  	

 CUSIP 90138P 209 

26 CAPITAL ACQUISITION CORP. 

UNITS CONSISTING OF ONE SHARE OF CLASS A COMMON STOCK AND ONE-HALF OF ONE WARRANT, 

EACH WHOLE WARRANT ENTITLING THE HOLDER TO PURCHASE ONE SHARE OF CLASS A 

COMMON STOCK 
 THIS
CERTIFIES THAT                is the owner
of                Units.     
 Each
Unit (“Unit”) consists of one (1) share of Class A common stock, par value $0.0001 per share (“Common Stock”), of 26 Capital
Acquisition Corp., a Delaware corporation (the “Company”), and one half of one redeemable warrant (the “Warrant”). Each whole Warrant entitles
the holder to purchase one (1) share (subject to adjustment) of Common Stock for $11.50 per share (subject to adjustment). Each Warrant will become exercisable on the later of (i) thirty (30) days after the Company’s completion of a
merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses (each a “Business Combination”), or
(ii) twelve (12) months from the closing of the Company’s initial public offering, and will expire unless exercised before 5:00 p.m., New York City Time, on the date that is five (5) years after the date on which the Company completes
its initial Business Combination, or earlier upon redemption or liquidation (the “Expiration Date”). The Common Stock and Warrants comprising the Units represented by this certificate are not
transferable separately prior to                , 2021, unless Cantor Fitzgerald & Co. elects to allow separate trading earlier, subject to the Company’s
filing of a Current Report on Form 8-K with the Securities and Exchange Commission containing an audited balance sheet reflecting the Company’s receipt of the gross proceeds of the Company’s initial
public offering and issuing a press release announcing when separate trading will begin. The terms of the Warrants are governed by a Warrant Agreement, dated as
of                 , 2021, between the Company and Continental Stock Transfer & Trust Company, as Warrant Agent, and are subject to the terms and provisions
contained therein, all of which terms and provisions the holder of this certificate consents to by acceptance hereof. Copies of the Warrant Agreement are on file at the office of the Warrant Agent at 1 State Street, 30th Floor, New York, New York 10004, and are available to any Warrant holder on written request and without cost. 

This certificate is not valid unless countersigned by the Transfer Agent and Registrar of the Company. 

This certificate shall be governed by and construed in accordance with the internal laws of the State of New York. 

Witness the facsimile signature of a duly authorized signatory of the Company. 

 

					
	                 
	 	            	  	
                    

	Authorized Signatory	 		  	Transfer Agent

 26 Capital Acquisition Corp. 

The Company will furnish without charge to each unitholder who so requests, a statement of the powers, designations, preferences and relative,
participating, optional or other special rights of each class of stock or series thereof of the Company and the qualifications, limitations, or restrictions of such preferences and/or rights. 

The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out
in full according to applicable laws or regulations: 
  

															
	TEN COM	  	—	  	as tenants in common	  	UNIF GIFT MIN	  	—	  		  	Custodian	  	
		  		  		  	ACT	  		  	  
	  		  	  

	TEN ENT	  	—	  	as tenants by the entireties	  		  		  	    (Cust)    	  		  	    (Minor)    
						
	JT TEN	  	—	  	as joint tenants with right of survivorship and not as tenants in common	  		  		  	under Uniform Gifts to Minors Act
		  		  		  		  		  	  

		  		  		  		  		  	(State)

 Additional abbreviations may also be used though not in the above list. 

For value received,                 hereby sell, assign and transfer
unto                 
 (PLEASE INSERT SOCIAL SECURITY OR
OTHER IDENTIFYING NUMBER OF ASSIGNEE) 
 (PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE) 

Units represented by the within Certificate, and do hereby irrevocably constitute and appoint 

Attorney to transfer the said Units on the books of the within named Company with full power of substitution in the premises. 

Dated 
  

	
	
                

	
	Notice: The signature to this assignment must correspond with the name as written upon the face of the certificate in every particular, without alteration or enlargement or any change whatever.

  

	
	 Signature(s) Guaranteed:
  

	
	THE SIGNATURE(S) MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C.
RULE 17Ad-15 (OR ANY SUCCESSOR RULE).

 In each case, as more fully described in the Company’s final prospectus
dated                , 2021, the holder(s) of this certificate shall be entitled to receive a pro-rata portion of certain funds
held in the trust account established in connection with its initial public offering only in the event that (i) the Company redeems the shares of Class A common stock sold in the Company’s initial public offering and liquidates
because it does not consummate an initial business combination within the time period set forth in the Company’s amended and restated certificate of incorporation, as the same may be amended from time to time (such date being referred to herein
as the “Last Date”), (ii) the Company redeems the shares of Class A common stock sold in its initial public offering in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation
to modify the substance or timing of the Company’s obligation to redeem 100% of the Class A common stock if it does not consummate an initial business combination by the Last Date, or (iii) if the holder(s) seek(s) to redeem for cash
his, her or its respective shares of Class A common stock in connection with a tender offer (or proxy solicitation, solely in the event the Company seeks stockholder approval of the proposed initial business combination) setting forth the
details of a proposed initial business combination. In no other circumstances shall the holder(s) have any right or interest of any kind in or to the trust account.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}]]